Nvidia Options Price in $280 Billion Earnings Swing 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Alibaba Raises $10.2 Billion to Expand AI Infrastructure 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Tesla Raises Cybertruck Prices by $5,000 in US 
California Seeks Paramount Divestitures in Warner Bros. Merger 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Anthropic IPO Could Challenge SpaceX’s Record $86 Billion Offering 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Add as a preferred source on Google
BERKELEY, Calif., May 02, 2018 -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that it will report financial results for the first quarter ended March 31, 2018 after market close on Tuesday, May 8, 2018, and host a conference call that day to review the results and provide a business update at 4:30pm ET/1:30pm PT.
To access the call, participants must dial (866) 548-4713 in the U.S. or (323) 794-2093 internationally, and use the conference ID 8635193. The live call will be webcast and can be accessed in the "Investors and Media" section of the company's website at www.dynavax.com. A replay of the webcast will be available for 30 days following the live event.
A replay of the conference call will be available for two weeks and can be accessed by dialing (844) 512-2921 in the U.S. or (412) 317-6671 internationally. The conference ID for the replay will be 8635193.
About Dynavax
Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company’s first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the United States. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development. For more information, visit www.dynavax.com.
Contact:
David Burke
Director, IR & Corporate Communications
510.665.7269
[email protected]
